Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29786218 | 1.00 | ADRB1 (0.59) | ADRB1MAPTNPC1KCNH2DRD2 | |
| SCHEMBL11074672 | 0.86 | ADRB1 (0.76) | ADRB1MAPTNPC1KCNH2DRD2 | |
| SCHEMBL19212406 | 0.84 | ADRB1 (0.69) | ADRB1MAPTNPC1KCNH2DRD2 | |
| SCHEMBL28906705 | 0.84 | PARP14 (0.48) | MAPTNPC1KMT2AMEN1ALDH1A1 | |
| SCHEMBL3667966 | 0.81 | L3MBTL1 (0.57) | ADRB1MAPTDRD2KMT2AMEN1 | |
| SCHEMBL27921921 | 0.81 | DRD2 (0.62) | ADRB1MAPTNPC1KCNH2DRD2 | |
| SCHEMBL27548199 | 0.81 | ADRB1 (0.56) | ADRB1MAPTNPC1KCNH2DRD2 | |
| SCHEMBL27739890 | 0.81 | KMT2A (0.65) | ADRB1MAPTNPC1KCNH2DRD2 | |
| SCHEMBL11889954 | 0.80 | ADRB1 (0.57) | ADRB1MAPTNPC1KCNH2KMT2A | |
| SCHEMBL1372927 | 0.80 | KCNH2 (0.69) | ADRB1MAPTNPC1KCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103313982-A | Phenyl-isoxazole derivatives and process for the preparation thereof | IL YANG PHARM CO LTD | 2013-09-18 | — | — | CN | claimed |
| CN-111377846-B | Piperazine benzamide derivative and application thereof | 江苏恩华药业股份有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-112566636-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-111377846-A | Piperazine benzamide derivative and application thereof | 江苏恩华药业股份有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-103313982-A | Phenyl-isoxazole derivatives and process for the preparation thereof | IL YANG PHARM CO LTD | 2013-09-18 | — | — | CN | disclosed |
| WO-2011094890-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | BRANE DISCOVERY S.R.L. (IT) | 2009-11-05 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| EP-1856083-A4 | CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS AND THE USES THEREOF | UNIV MICHIGAN (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | disclosed |
| EP-1856083-A2 | CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060247305-A1 | Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-11-02 | — | — | US | disclosed |
| WO-2006099193-A2 | CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247305-A1 | Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof | BCL2, BAD, BAX | ADRB1 4599/4885MAPT 3970/4885NPC1 4392/4885 |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | ADRB1 99/4885MAPT 201/4885NPC1 2959/4885 |
| US-20090275555-A1 | Substituted indole ligands for the ORL-1 receptor | OGFRL1, OPRL1, ORMDL3 | ADRB1 31/4885MAPT 3308/4885NPC1 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.